serena williams opens up about being on a glp-1 Are GLP-1s Performance-Enhancing Drugs? Serena Williams Tells Oprah Why

FIGURE 4 4 Comparative overview of mainstream GLP-1RAs Over the past 2 decades, several GLP-1RAs have entered clinical practice, including short-acting exenatide, intermediate-acting liraglutide, and long-acting formulations such as dulaglutide and semaglutide, as well as the newer dual agonist tirzepatide

Packed in convenient blister packs, each packaging contains ten tablets, ensuring ease of storage and use

This happens because the medication controls appetite, and once you stop taking it, hunger returns to normal levels

Notably, variants of uncertain significance in MC4R did not exert a significant impact on long-term surgical outcomes, indicating that only P/LP variants are associated with compromised long-term efficacy